Hematology

Filter

gene therapy

EAHAD 2026: Nine-Year Outcomes of Gene Therapy

February 2026

Nine-year data show sustained safety and reduced bleeding after gene therapy in haemophilia B, although enrichment for full viral capsids did not deliver clear clinical advantages.

Shaji Kumar

Hema Now: Episode 14: Personalised Approaches in Myeloma Treatment

Shaji Kumar, Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA

EBMT 2025 Interview: Chiara Nozzoli

In this interview, Chiara Nozzoli, speaks on her career journey and her work in haematopoietic stem cell transplantation, particularly in…

Review of the 18th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

The 18th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) was held this year in Milan, Italy, from…

Entering a New Era in Protection in Haemophilia A

Haemophilia A (HA), defined by factor VIII (FVIII) levels ≤40 IU/dL, is a chronic condition with consequences beyond bleeding…

RNA Sequencing Uncovers New Subtypes of B Cell Precursor Leukaemia

A recent study has demonstrated how RNA sequencing can enhance the genetic classification of B cell precursor acute lymphoblastic leukaemia patients…

Reduced-Dose Apixaban Effective for Cancer-Related Blood Clots

Reduced-dose apixaban prevents recurrent blood clots in cancer patients, with fewer bleeding complications, offering a safer treatment option.

Key Mechanism for Haematopoietic Stem Cell Regeneration Unlocked

A groundbreaking study has revealed new insights into the molecular mechanisms that govern the activation and quiescence of haematopoietic stem and progenitor cells.

Jonathan Sackier, hema now highlights

Hema Now: Episode 13: Hema Now Highlights

Take look back at Jonathan Sackier’s highlights from the Hema Now podcast so far, exploring CAR-T therapies, bispecific antibodies and more.

Loading posts...

« Previous 1 … 21 22 23 24 25 … 100 Next »